The effects of tibolone
Review
OA: closed
public-domain-us
AI-generated summary
Tibolone, a non-bleeding hormone replacement therapy that induces endometrial atrophy via progestogenic metabolites, offers clinical utility for postmenopausal women and those with a history of endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Tibolone is a non-bleeding form of hormone replacement therapy (HRT). When ingested, it is broken down into metabolites, of which the progestogenic metabolite predominates at the level of the endometrium, so that an atrophic endometrium is produced. For the postmenopausal woman, the availability of non-bleeding HRT has great appeal, and compliance is substantially improved. Other clinical situations in which tibolone is particularly useful include: women who have had hormone-dependent tumors in the past, women who have had endometriosis and women taking gonadotropin-releasing hormone agonists.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-19T06:17:24.038039+00:00
- pubmed
- last seen: 2026-10-08T22:00:41.816812+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine